Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents

NCT04951388 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT04951388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04951388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 2
Overall status
Completed
Start date
July 22, 2021
Completion date
March 21, 2022
Enrollment
399 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 vaccine